No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
FENC250117C7500
- 0.20
- 0.000.00%
15min DelayClose Jan 6 16:00 ET
0.00High0.00Low
0.20Open0.20Pre Close0 Volume5 Open Interest7.50Strike Price0.00Turnover151.01%IV26.64%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.2453Delta0.2026Gamma30.40Leverage Ratio-0.0237Theta0.0004Rho7.46Eff Leverage0.0032Vega
Intraday
- 5D
- Daily
News
Fennec's Pedmarqsi Gets Nod From U.K. Regulators
Craig-Hallum Initiates Fennec Pharmaceuticals(FENC.US) With Buy Rating
Craig-Hallum Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating
Express News | Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by Nice for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
Fennec Pharmaceuticals Brief: Includes Elimination of Near US$1.5 Million in Annual Interest Expense and Potential Equity Overhang of Near 1.6 Million Shares